3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
45
Stomach Neoplasms
20
Pancreatic Neoplasms
20
Rectal Neoplasms
16
Adenocarcinoma Of Esophagus
14
Esophageal Neoplasms
13
Colonic Neoplasms
12
Neoplasms
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
11
Urinary Bladder Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Esophageal Squamous Cell Carcinoma
7
Adenocarcinoma
7
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Lung Neoplasms
4
Gastrointestinal Neoplasms
4
Endometrial Neoplasms
4
Carcinoma
4
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Advanced Solid Tumors
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Oropharyngeal Neoplasms
2
Melanoma
2
Interventions
Gemcitabine
6
Cisplatin
6
pembrolizumab
3
durvalumab
3
Oxaliplatin
3
tivozanib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
trametinib
1
tislelizumab
1
olaparib
1
atezolizumab
1
Yttrium-90
1
Stents
1
Radiosurgery
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Floxuridine
1
Dexamethasone
1
Capecitabine
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Fluorouracil
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts